Dalcor taps new CEO Fouzia Laghrissi-Thode as pivotal PhIII looms; Kelly Martin settles in at Novan; Edward Stewart takes over Commense
→ AstraZeneca vet Fouzia Laghrissi-Thode will be leading DalCor Pharmaceuticals through patient enrollment into its pivotal Phase III trial. The newly minted CEO has her work cut out for her — London-based DalCor is trying to prove that dalcetrapib, a CETP inhibitor Roche abandoned, has a strong cardio benefit for a subgroup of patients with a certain genotype by testing it in 6000 people. Laghrissi-Thode began tackling this field at Roche, where she was a franchise leader for several drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.